<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564148</url>
  </required_header>
  <id_info>
    <org_study_id>AVAST-ro-1</org_study_id>
    <secondary_id>SITE-App</secondary_id>
    <nct_id>NCT00564148</nct_id>
  </id_info>
  <brief_title>Intravitreal Avastin in Proliferative Retinopathies</brief_title>
  <acronym>SITE-App</acronym>
  <official_title>Intravitreal Injections With Avastin in Proliferative Retinopathies Related to the Production of VEGF Having Different Causes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthalmological Association Edelweiss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ophthalmological Association Edelweiss</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study intends to assess the effect of Avastin injections in different proliferative
      retinopathies due to different causes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proliferative retinopathies due to different causes represent important causes for the visual
      acuity loss. Conventional treatments may sometimes improve the visual function, whereas other
      times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser
      treatments.

      Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an
      important tool for certain difficult situations in which at the ocular fundus, out of
      different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new
      pathologic vessels appear, causing devastating changes in the posterior and anterior segment
      as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The following parameters will be assessed in order to evaluate the Avastin effect: visual acuity, lesions's area at the ocular fundus</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The intraocular pressure will be measured during the whole study in order to assess the possible side effects of Avastin injections</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Retinal Neovascularization</condition>
  <arm_group>
    <arm_group_label>A,1, II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively</description>
    <arm_group_label>A,1, II</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of a proliferative retinopathy (AGE RELATED MACULAR
             DEGENERATION,DIABETIC PROLIFERATIVE RETINOPATHY, etc)

          -  distance acuity &lt; 0.5

          -  age &gt; 20 years

        Exclusion Criteria:

          -  noncooperative patients

          -  ocular infections / inflammations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NARCISA IANOPOL, researcher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmological Association Edelweiss</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochiul Diabetic</name>
      <address>
        <city>Iasi</city>
        <zip>700377</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>NARCISA IANOPOL</name_title>
    <organization>Ophthalmological Association Edelweiss</organization>
  </responsible_party>
  <keyword>antiVEGF therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Retinal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

